Device Firms Eye Rocketing Pay-For-Performance Insurance Plans Warily
This article was originally published in The Gray Sheet
Executive Summary
Industry group AdvaMed says it is concerned a rapid shift toward pay-for performance and financial risk-sharing models by commercial insurers will discourage providers from giving patients newer devices and could stifle innovation.
You may also be interested in...
Medicare’s ACO Final Rule Responds To Provider Concerns, But Leaves Device Industry Dissatisfied
Although CMS’ newly finalized rule on accountable care organizations has allayed health care providers’ fears of a program too burdensome to bother with, medical device manufacturers remain worried that ACOs will curb patient access to their products.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.